Oct 28HHS draft policy lets licensed pharmacies compound six peptides, including BPC-157. What changed and what did not.
Skip to content
PeptideAgent

ExplainerUpdated 7 min read

TB-500 vs thymosin beta-4: is it the same peptide?

FDA says TB-500 and thymosin beta-4 are not the same substance. What each one is, which one the human and animal studies used, capsules and sprays, and the cancer question.

By the PeptideAgent Editorial Team. Editorially reviewed, not clinically reviewed.  Last verified

The short answer: no. TB-500 and thymosin beta-4 are different substances. FDA's July 2026 briefing on TB-500 says so directly: "thymosin beta-4 and TB-500 are not the same substance." [17] Thymosin beta-4 (often shortened to TB4 or Tβ4) is a natural 43 amino acid protein that the body releases after injury. TB-500 is a synthetic, acetylated copy of just 7 of those amino acids, the segment known as LKKTETQ, which is what doping laboratories found when they tested a product sold under the name. [3] [4] Marketing for TB-500 does not always make clear which of the two a product contains, so the label alone does not tell you what is inside.

The practical point: every human trial people cite for "TB-500", and the well-known rodent wound and heart results, used full-length thymosin beta-4, not TB-500. FDA's literature search found no article in which TB-500 was administered to humans and no animal study testing whether TB-500 itself promotes wound healing. [17]

Is thymosin beta-4 the same as TB-500?

Thymosin beta-4 is a small protein made by many cell types. It binds actin, the protein that lets cells move and change shape, and after injury it is released by platelets and immune cells. It promotes cell migration and new blood vessel growth, reduces inflammation, and in animal models reduces scarring. [5]

The LKKTETQ segment at positions 17 to 23 is described in the doping literature as the part of thymosin beta-4 responsible for actin binding and cell migration. [3] The equine doping study describes TB-500 as a veterinary preparation whose key ingredient is a synthetic version of that segment, with an acetyl group added to one end. [3] A Belgian doping laboratory confirmed the acetylated fragment in a TB-500 product and suggested a way to test for it in blood and urine. [4]

Sharing a segment does not make the fragment behave like the whole protein. One mouse study found that the same 7 amino acid sequence without the acetyl group sped wound repair in aged mice about as well as full-length thymosin beta-4. [19] TB-500 is the acetylated form, and FDA says that result cannot be directly extrapolated to it. [17]

In short:

  • Thymosin beta-4 (TB4): the full-length natural protein. It has phase 1 safety trials and phase 2 eye and wound trials in people, plus animal data in wound, heart, eye, and brain models.
  • TB-500: a synthetic acetylated 17 to 23 fragment. It has no published human study and no animal study of wound healing, and its claimed effects are borrowed from studies of the full protein. [17]
  • Both: not FDA approved, and both are named on the WADA list. [16]

TB4 vs TB-500: which has human evidence?

Full-length thymosin beta-4 has a small but real human record. Every result in this list is a thymosin beta-4 result, not a TB-500 result.

  • Wound healing (animal): in rats, thymosin beta-4 increased wound reepithelialization by 42% at day 4 and up to 61% at day 7 versus saline. [6]
  • Dry eye (human): a phase 2 trial of a thymosin beta-4 eye drop in 72 adults missed both primary endpoints, although several secondary measures improved. [7]
  • Safety (human): two randomized, placebo-controlled phase 1 studies in healthy volunteers, the second using a recombinant form in China, gave intravenous thymosin beta-4 across a range of doses and reported only mild to moderate adverse events, with no serious events or dose-limiting toxicity. [8] [9]
  • Skin ulcers (human): a review of two phase 2 trials in venous stasis and pressure ulcers reported faster healing, by almost a month, in patients who healed. [10]

None of this was done with TB-500, and none of it tested injections under the skin for muscle, tendon, or joint injuries. TB-500 itself has not been tested in any of these ways. Its own indexed record is a horse study and a rat study that tracked how the peptide is absorbed and broken down, plus a 2024 cell study in which TB-500 did not close scratch wounds in cultured fibroblasts while one of its breakdown products did. [3] [18] A 2026 review of peptides used in sports medicine concluded that rigorous human safety data for unapproved peptides such as TB-500 are scarce. [13] That is why our evidence grade for TB-500 is animal only: trials of a different substance do not raise it. The wound healing page lists what does have human evidence.

TB-500 capsules, nasal spray, and TB-500 spray

The human thymosin beta-4 studies used eye drops, intravenous infusion, or a topical gel on wounds. [7] [8] [10] We found no published study of TB-500 or thymosin beta-4 taken as a capsule or nasal spray, in people or animals, and no data on whether either form is absorbed. The doping laboratory work measured the fragment in the blood and urine of horses after administration, not in people taking oral or nasal products. [3] Capsules and sprays are therefore untested on the most basic question: whether the peptide reaches the bloodstream at all.

Does thymosin beta-4 cause cancer?

No study has shown that taking thymosin beta-4 or TB-500 causes cancer in people. But there is a real theoretical concern, and it follows from how the protein works.

The same activities that help wounds heal, cell migration and new blood vessel growth, are also what tumors use to spread. In mouse and cell experiments, thymosin beta-4 was required for a gene program linked to metastasis, cancer cells lacking it spread less in mice, and high thymosin beta-4 expression was associated with poorer prognosis across several human cancer datasets. [11] In thyroid tissue, thymosin beta-4 was barely detectable in normal and benign samples but overexpressed in several thyroid cancers, and higher expression tracked with more advanced disease. [12]

These findings describe the body's own thymosin beta-4 inside tumors. They do not show that an injected product starts a cancer. They are a reason why people with a current or past cancer should raise any thymosin beta-4 product with their oncologist, and why the lack of long-term human safety data matters.

Why the difference matters

The TB4 vs TB-500 distinction is not a naming technicality. The two molecules differ in size, in how they are made, and in what has been studied. A claim drawn from the full-length protein, such as the phase 1 safety results, does not apply to a 7 amino acid fragment, and the fragment has never had its own human safety study. [4] [8] FDA's briefing also identified no toxicity studies of TB-500. [17]

It also matters for testing. Doping laboratories built their detection methods around the acetylated fragment and its breakdown products, because that is what they found in the product. [3] For anyone weighing a claim about TB-500, the first question is which molecule the claim is actually about.

TB-500 with BPC-157 and other blends

TB-500 is most often sold alongside BPC-157, the combination covered on our Wolverine stack page. It also appears in the GLOW blend with GHK-Cu. No trial has tested TB-500 in combination with anything. Our BPC-157 vs TB-500 comparison shows that neither has a human trial for injury healing, and our thymosin alpha-1 vs TB-500 comparison explains how two peptides with "thymosin" in their names differ in both biology and evidence.

TB-500 is not an FDA approved drug. At the July 23 to 24, 2026 meeting of FDA's Pharmacy Compounding Advisory Committee, FDA presented TB-500 for the 503A bulks list. [14] FDA's drug center recommended against listing it, and the advisory committee voted in favor. [1] It is not on that list, and FDA has proposed no rule. [15] On October 28, 2026, HHS released a draft enforcement discretion policy saying it does not intend to take enforcement action against a state-licensed pharmacy, federal facility, or licensed physician that compounds single-ingredient TB-500 by subcutaneous or intramuscular injection, on a patient-specific prescription, when all of the policy's conditions are met. [1] That is not an FDA approval or a 503A bulks listing, it is not binding, and HHS may revisit it; the notice was published in the Federal Register on October 30, 2026. [2] The policy names TB-500, not full-length thymosin beta-4. Our explainer on the draft HHS policy covers its conditions and what did not change. Products sold for research use are not lawful for human use and are not verified for identity, which matters more than usual here, because the name is used loosely for two different substances.

For athletes, WADA lists thymosin beta-4 and TB-500 by name under section S2, prohibited at all times. [16]

The TB-500 regulatory timeline tracks its regulatory status, and the TB-500 cost page explains why advertised prices are not a comparable figure.

What's actually offered, and what that means for you

Licensed compounding pharmacies, clinics, and telehealth prescribers openly offer many unapproved peptides, and prescribers write prescriptions for them. [20] [21] [22]

What that means for you

  • A pharmacy that compounds TB-500 relies on HHS's draft policy, which has strict conditions and which HHS can revisit, so it carries some regulatory risk. Compounding it outside those conditions, such as in a blend or by another route, has no federal basis. [1]
  • No FDA oversight of the specific product: FDA does not check a compounded drug's safety, effectiveness, or quality before it is sold. [23]
  • State boards can act. On August 19, 2026, Mississippi's medical, nursing, and pharmacy boards said no licensed provider may prescribe, recommend, supply, or administer a peptide that is not FDA approved, and that a consent form does not remove the provider's liability. [24]
  • Louisiana acted by statute: Act 374, in effect August 1, 2026, bars its licensing boards from prohibiting peptides only when they come from a pharmacy or outsourcing facility that complies with federal compounding law. It does not make any peptide eligible to compound. [25] [26]

If you're going ahead anyway

Each step is on the TB-500 page: check the pharmacy's license, what a legitimate prescription and consult look like, why this is safer than a research-use-only product, and questions to ask. These steps lower some risks. They do not make a compounded product safe, and FDA has not reviewed it. [23]

Decisions about starting, stopping, or combining any treatment belong with a licensed clinician who knows your history.

Frequently asked questions

Is thymosin beta-4 the same as TB-500?

No. FDA's July 2026 briefing says thymosin beta-4 and TB-500 are not the same substance. Thymosin beta-4 is a naturally occurring 43 amino acid protein. TB-500 is a synthetic, N-terminally acetylated copy of a 7 amino acid segment of it (LKKTETQ, positions 17 to 23), which is what doping laboratories found in a product sold under that name. [3] [4] [17]

Which has more human evidence, TB4 or TB-500?

Full-length thymosin beta-4 does. It has phase 1 safety trials in healthy volunteers, a phase 2 dry eye trial that missed its primary endpoints, and phase 2 wound trials. TB-500 has none: FDA's literature search found no article in which TB-500 was administered to humans, so none of those results belong to it. [7] [8] [9] [10] [17]

Does thymosin beta-4 cause cancer?

No human study has shown that taking thymosin beta-4 or TB-500 causes cancer. The concern is theoretical: laboratory and mouse work links high thymosin beta-4 activity in tumors to spread and poorer prognosis, and tumor samples from thyroid cancers show higher expression than benign tissue. [11] [12]

Is TB-500 legal?

It is not FDA approved and not on the 503A bulks list. At FDA's July 2026 compounding advisory committee meeting, FDA's drug center recommended against listing it, and the committee voted in favor. Under a draft HHS policy released October 28, 2026, HHS says it does not intend to take enforcement action against licensed compounding of single-ingredient TB-500 by subcutaneous or intramuscular injection on a patient-specific prescription, when all of the policy's conditions are met. That is not an FDA approval, and HHS may revisit it. Full-length thymosin beta-4 is not covered. WADA names both thymosin beta-4 and TB-500 as prohibited. [14] [15] [16]

Sources

Numbered citations in the article point to these primary sources. PubMed entries link to the indexed abstract. Evidence grades follow our methodology.

  1. [1]HHS: Enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances, with Appendix A and Appendix B (draft, October 2026)2026
  2. [2]Federal Register: Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances; Notice of availability (HHS Office of the Secretary, FR Doc. 2026-22192, Docket No. HHS-OASH-2026-0496, published October 30, 2026)Federal Register, 2026
  3. [3]Ho EN et al. Doping control analysis of TB-500, a synthetic version of an active region of thymosin beta 4, in equine urine and plasma by liquid chromatography-mass spectrometry. J Chromatogr A 2012PubMed 23084823, 2012
  4. [4]Esposito S et al. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal 2012PubMed 22962027, 2012
  5. [5]Goldstein AL et al. Thymosin beta4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther 2012PubMed 22074294, 2012
  6. [6]Malinda KM et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol 1999PubMed 10469335, 1999
  7. [7]Sosne G et al. Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, phase II clinical trial. Clin Ophthalmol 2015PubMed 26056426, 2015
  8. [8]Ruff D et al. A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers. Ann N Y Acad Sci 2010PubMed 20536472, 2010
  9. [9]Wang X et al. A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin beta 4 in healthy Chinese volunteers. J Cell Mol Med 2021PubMed 34346165, 2021
  10. [10]Treadwell T et al. The regenerative peptide thymosin beta 4 accelerates the rate of dermal healing in preclinical animal models and in patients. Ann N Y Acad Sci 2012PubMed 23050815, 2012

More from the blog